Biogen Inc
NASDAQ: BIIB
$164.89
-$0.90 (-0.5%)
Closing Price on November 14, 2024
BIIB Articles
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
Published:
Last Updated:
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
Published:
Last Updated:
Alkermes saw its shares make a handy gain to start off the week, after the firm announced that it has entered into a global license agreement with Biogen.
Published:
Last Updated:
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Cabot Oil & Gas, CenturyLink, NetApp, Square, T-Mobile and Wix.com.
Published:
Last Updated:
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include AMD, Apple, Biogen, Capital One, Chipotle Mexican Grill, General Motors and 3M.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday include Biogen, Equifax, Foot Locker, General Electric, NVIDIA, Rio Tinto and Roku.
Published:
Last Updated:
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include Biogen, Carbonite, Celgene, Emerson Electric, Kinder Morgan, Netflix and UnitedHealth.
Published:
Last Updated:
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Published:
Last Updated:
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
Published:
Last Updated:
If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech company, it would be in a successful treatment of Alzheimer's disease.
Published:
Last Updated: